Clinical Trial to Evaluate the Efficacy and Safety of 'DW1601' in Acute Bronchitis

A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis

A Multicenter, Randomized, Double-Blind, Parallel, Active-controlled, Superiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1601 Compared to DW16011 and DW16012 for Acute Bronchitis

Inclusion Criteria:

• Both gender, 19 years ≤ age ≤ 80 years
• Bronchitis Severity Score* ≥ 5point at Visit 2 (Randomized Visit)
• Acute bronchitis within 48hr based on Visit 2 (Randomized Visit)
• Those who can comply with the requirements of clinical trials
• Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

• Patients who investigators determines to severe respiratory disease that would interfere with study assessment
• Patients with systemic infections requiring systemic antibiotic therapy
• patient with hemostatic disorder